2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-169463
    11-Hydroxy cannabinol 30432-08-7 98%
    11-Hydroxy cannabinol (Compound 5b) is an active metabolite of Cannabinol.
    11-Hydroxy cannabinol
  • HY-169609
    JNK-IN-22 771503-50-5 98%
    JNK-IN-22 (Compound 58) is a JNK-1 inhibitor.
    JNK-IN-22
  • HY-169707
    GCGR antagonist 3 1421349-19-0 98%
    GCGR antagonist 3 (example 1) is an antagonist of the glucagon receptor (GCGR) and can be used in diabetes research.
    GCGR antagonist 3
  • HY-169724
    RBx-0597 929105-33-9 98%
    RBx-0597 is a potent and selective DPP-IV inhibitor, demonstrating IC50 values of 32, 31, and 39 nM against human, mouse, and rat plasma DPP-IV, respectively. RBx-0597 shows potential for type 2 diabetes research.
    RBx-0597
  • HY-169736
    JNK-IN-21 756849-36-2 98%
    JNK-IN-21 (Compound 62) is a JNK-1 inhibitor.
    JNK-IN-21
  • HY-169737
    Inulobiose 470-58-6 98%
    Inulobiose is a difructan disaccharide that can be isolated from Pistacia vera L.. Inulobiose inhibits α-glycosidase and α-amylase activities with IC50s of 1.87 and 40.72 mg/mL, respectively. Inulobiose can be used for the research of diabetes and glomerular filtration rate testing.
    Inulobiose
  • HY-169739
    DG 381B 564-16-9 98%
    DG 381B (compound 62) is a 11β-HSD1 and 11β-HSD2inhibitor.
    DG 381B
  • HY-169750
    Hydroxytyrosol 1-O-glucoside 76873-99-9 98%
    Hydroxytyrosol 1-O-glucoside (Dopaol glucoside) is a glycoside with antioxidant activity. Hydroxytyrosol 1-O-glucoside is also an epoxide hydrolase 2 inhibitor.
    Hydroxytyrosol 1-O-glucoside
  • HY-169768
    (E/Z)-Etherolenic acid 2247927-22-4 98%
    (E/Z)-Etherolenic acid is a divinyl ether oxylipin and is a metabolite of Linolenic acid.
    (E/Z)-Etherolenic acid
  • HY-169783
    Gigantetrocin 134955-48-9 98%
    Gigantetrocin is a bioactive annonacetyl coenzyme from goniothalamus giganteus.
    Gigantetrocin
  • HY-169784
    PPI-1040 1436673-69-6 98%
    PPI-1040 is an orally bioavailable vinyl ether synthetic plasmalogen. PPI-1040 acts as a precursor of plasmalogen. PPI-1040 increases plasmalogen levels in plasmalogen-deficient mice and normalizes hyperactive behaviors in these mice. In wild-type mice, PPI-1040 retains the sn-1 vinyl ether group and sn-3 phosphoethanolamine group, and is converted into endogenous ethanolamine plasmalogen. PPI-1040 can be used in studies related to rhizomelic chondrodysplasia punctata.
    PPI-1040
  • HY-169793
    Thalicpureine 218900-91-5 98%
    Thalicpureine (compound 12) is a secondary metabolite.
    Thalicpureine
  • HY-169799
    Cholylglycylamidofluorescein 168912-70-7 98%
    Cholylglycylamidofluorescein (CGamF) is a fluorescent probe for hepatic bile acid transport. Cholylglycylamidofluorescein is composed of Cholic acid conjugated via a glycylamino linkage to fluorescein. (Ex/Em = 492/515 nM in Aqueous)
    Cholylglycylamidofluorescein
  • HY-169821
    SGLT1/2-IN-8 2206679-16-3 98%
    SGLT1/2-IN-8 (compound 8) is a potent and orally active SGLT1/2 dual inhibitor with IC50 values of 4 nM and 1 nM, respectively. SGLT1/2-IN-8 exhibits anti-hyperglycemic effects and can be utilized in relevant research.
    SGLT1/2-IN-8
  • HY-169846
    CL5D 2488745-53-3
    CL5D is an activator of protein deacetylase SIRT6. CL5D can significantly enhance the deacetylation activity of SIRT6 and improve its catalytic efficiency. CL5D regulates SIRT6 activity by promoting conformational changes, especially dependent on the role of Arg-65 residue. CL5D can be used to study the activation mechanism of SIRT6 and its function in metabolism, DNA repair and aging.
    CL5D
  • HY-169865
    Bac-429 2227449-70-7 98%
    Bac-429 (compound 23) is a N-acyl amino acid analog that stimulates mitochondrial respiration.
    Bac-429
  • HY-169907
    Anticancer agent 258 2891984-12-4 98%
    Anticancer agent 258 is an imidazo [1,2-B][1,2,4] triazol derivative. Anticancer agent 258 regulates the activity of nuclear receptors. Anticancer agent 258 has an EC50 of 63 nM against Nurr in N2A cells. Anticancer agent 258 has IC50 of 0.1 pM for Nur77 in HEK293 cells. Anticancer agent 258 can be used in the study of cancer, metabolic diseases and neurological disorders.
    Anticancer agent 258
  • HY-169953
    BT-Amide 98%
    BT-Amide is the orally active inhibitor for Pyk2 kinase with IC50 of 44.69 nM. BT-Amide prevents glucocorticoid-induced bone loss, exhibits bone protective activity in C57BL/6 mouse.
    BT-Amide
  • HY-170220
    PacFA Ceramide 1262788-58-8
    PacFA Ceramide is a 15-carbon long photoactivatable and clickable fatty acid. PacFA Ceramide can be used for the analysis of protein-lipid interactions in living cells.
    PacFA Ceramide
  • HY-170317
    EA-89-Succinic acid 98%
    EA-89-Succinic acid (Compound 26) is the active control of the target protein ligand EA-89 (HY-170314), which can be used for the synthesis of PROTAC .
    EA-89-Succinic acid
Cat. No. Product Name / Synonyms Application Reactivity